Coivas Review

What Coivas charges

• Semaglutide: $149/mo — per month, billed $447 every three months; a new-patient intro runs $119 a month, billed $357 for the first three
• Tirzepatide: $229/mo — per month, read from the seller's own column of its comparison table, which is the only place the figure renders
• Sermorelin: $199/mo — per month, billed $597 every three months; a new-patient intro runs $119 a month, billed $357 for the first three
• NAD+: $149/mo — per month after a $99 first month, on the quarterly plan; a monthly plan runs $199 after a $119 first month
• NAD+: $119/mo — per month after an $89 first month, on the quarterly plan; a monthly plan runs $129 after a $99 first month

Three legal names for one seller

Its terms and privacy policy call the operator "WellVi LLC d/b/a Coivas".

Its contact block calls it "Coivas Health, Inc.", and its footer carries a copyright line for "Coivas Health" with no suffix at all.

All three are recorded and none is treated as authoritative. A reader who wants to look the company up in a state registry has to guess which name to type.

The tirzepatide figure lives only inside a comparison table

Its "See how Coivas compares" table has four columns, three of which belong to unnamed rivals. The seller's own column was identified three separate ways before any figure was taken from it.

Its membership row reads None, matching the page's sentence that "There are no separate membership or per-visit fees"; its clear-pricing row reads Yes against three Nos; and its semaglutide figure matches the hero above.

The molecule toggle in that hero is JavaScript and renders no tirzepatide price in the served document, so the table is the only place that price exists.

It dates its prices and reconciles its own arithmetic

The treatment page prints "Pricing as of August 2026", which turns a number into a dated observation rather than an open-ended claim.

Every quarterly total it publishes multiplies out correctly against the per-month figure beside it, and every product carries both an introductory rate and the standing rate that follows it.

It also states the regulatory position plainly: "The FDA does not review or approve compounded medications for safety or effectiveness."

The clinical group is named; the pharmacy is not

It names its clinical group and publishes an address, which is more than most sellers here do.

The dispenser is described as a class rather than a company: "Coivas partners with state-licensed 503A compounding pharmacies and 503B outsourcing facilities… The dispensing pharmacy may vary."

Its fifty-state claim is not credited, because its own terms immediately qualify it — the service is "available to residents of states where we are authorized to provide telehealth services", and no list is published.

How we verified this

• Identified the seller's own column in its comparison table three independent ways — its membership row, its clear-pricing row and its semaglutide figure matching the hero — before recording anything from it.
• Multiplied every published quarterly total against its stated per-month figure and confirmed each one reconciles.
• Read the terms, the contact block and the footer and recorded all three company names rather than picking one.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand, the operating company its terms name and its named clinical group against the live federal warning-letter table, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run. Nothing attaches to any of the three.